Biogen tops quarterly estimates on rare-disease drug strength

What happened

Biogen beat Wall Street estimates for third-quarter results as demand for rare-disease and Alzheimer's treatments offset declines in its multiple sclerosis business. The drugmaker also announced a $5.6 billion buyout of Apellis Pharmaceuticals, adding drugs Syfovre and Empaveli.

Confirmed

Global impact / market context

The Apellis deal shifts Biogen further toward rare diseases, where fewer rivals and higher prices can support profit per sale. Management expects at least $250 million in annual cost savings and other benefits, which could help stabilize revenue as multiple sclerosis sales shrink.

Analyst inference

A Citi analyst called the quarter early green shoots, saying growth products plus Apellis could stabilize revenue and support an earnings recovery, with 2026 increasingly seen as the trough, meaning the low point. That view rests on product sales rather than one trading session.

Analyst inference

What to watch

1. Syfovre sales rose 27% to $191 million and Empaveli brought in $52 million, up 92% from a year earlier. Rare-disease portfolio sales jumped 27% to $676 million. Confirmed
2. Management expects the Apellis acquisition to add to adjusted earnings in 2027 and to generate at least $250 million in annual cost savings and other benefits by the end of that year. Proposed
3. Late-stage trial results over the next year, including lupus drug litifilimab and a kidney-disease treatment, could shape whether Biogen meets its long-term growth goals. Analyst inference

Evidence

• Original source link unavailable